TLR7/8 agonist 1 dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: TLR7/8 agonist 1 dihydrochloride
• 英文别名: 1-[[4-(aminomethyl)phenyl]methyl]-2-butylimidazo[4,5-c]quinolin-4-amine;dihydrochloride
• 化学式: C22H27Cl2N5
• 分子量: 432.4
• InChiKey: YKZCFKIAMHQQAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82.8
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• [EN] TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME<br/>[FR] LIPOPEPTIDES AGONISTES DU RÉCEPTEUR 2 DE TYPE TOLL, ET PROCÉDÉ DE FABRICATION DE CEUX-CI
  申请人：UNIV KANSAS

  公开号：WO2014113634A1

  公开（公告）日：2014-07-24

  The present disclosure is directed to a novel class of toll-like receptor 2-agnonistic (TLR2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, TLR2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most successful medical interventions against infectious disease.

  本公开涉及一类新型的特定结构的类胜肽化的类Toll样受体2激动剂（TLR2）脂肽化合物，以及制备这些化合物的合成方法。这些化合物在人类TLR2中具有高激动活性，并可用作疫苗佐剂。疫苗可能是针对传染病最成功的医学干预之一。
• TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME
  申请人：UNIVERSITY OF KANSAS

  公开号：US20150337009A1

  公开（公告）日：2015-11-26

  The present disclosure is directed to a novel class of toll-like receptor 2-agonistic (TLR2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, TLR2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most successful medical interventions against infectious disease.

  本公开涉及一种新型的具有特定结构的Toll样受体2-激动剂（TLR2）脂肽化合物及其合成方法。这些化合物在人类（而非小鼠）的TLR2上具有高效的激动活性，并可用作疫苗佐剂。疫苗可能是预防传染病最成功的医疗干预措施之一。
• AMPHIPHILIC OLIGODEOXYNUCLEOTIDE CONJUGATES AS ADJUVANT ENHANCERS
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20200268879A1

  公开（公告）日：2020-08-27

  Amphiphilic oligonucleotide conjugates that enhance adjuvant function are disclosed. The conjugates typically include: a lipophilic component, and conjugated thereto (directly or indirectly) an immunomodulating oligonucleotide that, if it were not conjugated to the lipophilic component, would suppress TLR7 and/or TLR8 stimulation. In the presence of albumin, these conjugates significantly enhance adjuvant function, in particular the function of TLR7/8-mediated adjuvants such as an imidazoquinolinamine. The conjugates can be administered, along with an adjuvant compound, to a subject in order to cause and/or enhance an immune response (for instance, to an infectious agent or a cancer antigen) in the subject.
• US9676818B2
  申请人：——

  公开号：US9676818B2

  公开（公告）日：2017-06-13